Pfizer Inc. (NYSE:PFE) Shares Sold by First Business Financial Services Inc.

First Business Financial Services Inc. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 10.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,496 shares of the biopharmaceutical company’s stock after selling 834 shares during the period. First Business Financial Services Inc.’s holdings in Pfizer were worth $269,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. 1 North Wealth Services LLC purchased a new position in Pfizer in the third quarter worth approximately $29,000. Bourgeon Capital Management LLC purchased a new stake in shares of Pfizer during the 3rd quarter worth approximately $32,000. Evolution Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $34,000. IMA Wealth Inc. lifted its position in shares of Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 477 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Pfizer during the 3rd quarter worth approximately $36,000. Hedge funds and other institutional investors own 71.52% of the company’s stock.

Shares of Pfizer stock traded up $0.14 during trading on Friday, reaching $37.05. The company’s stock had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. The company has a 50-day moving average price of $36.62 and a two-hundred day moving average price of $39.26. The firm has a market cap of $207.30 billion, a PE ratio of 12.35, a P/E/G ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.13. The business had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The company’s quarterly revenue was down 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 EPS. On average, analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.89%. Pfizer’s payout ratio is 48.00%.

Several analysts have recently weighed in on the stock. Bank of America assumed coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. UBS Group restated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research report on Monday, August 5th. Morgan Stanley cut their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 target price on shares of Pfizer in a report on Wednesday. Nine analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $44.02.

In other news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $34.72 per share, with a total value of $104,160.00. Following the purchase, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Trading on Margin

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.